CD8A and neoplasm: The heterologous multi-epitope vaccination not only induced antigen-specific CD8+ T-cell responses in the periphery but also in the tumor and tumor-dLNs to all three antigens, thereby lowering the risk of escape mutants due to loss of antigen expression/mutations [14].